Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

Biden administration approved $735 million arms sale to Israel - sources

Published 05/17/2021, 12:36 PM
Updated 05/17/2021, 06:05 PM
© Reuters. Israeli soldiers stand by an artillery unit as it fires near the border between Israel and the Gaza strip, on the Israeli side May 17, 2021. REUTERS/Amir Cohen

© Reuters. Israeli soldiers stand by an artillery unit as it fires near the border between Israel and the Gaza strip, on the Israeli side May 17, 2021. REUTERS/Amir Cohen

By Patricia Zengerle

WASHINGTON (Reuters) - President Joe Biden's administration approved the potential sale of $735 million in precision-guided weapons to Israel, and congressional sources said on Monday that U.S. lawmakers were not expected to object to the deal despite violence between Israel and Palestinian militants.

Three congressional aides said Congress was officially notified of the intended commercial sale on May 5, as part of the regular review process before major foreign weapons sales agreements can go ahead.

The sale was first reported by the Washington Post.

Congress was informed of the planned sale in April, as part of the normal informal review process before of the formal notification on May 5. Under U.S. law, the formal notification opens up a 15-day window for Congress to object to the sale, which is not expected despite the ongoing violence.

The sale of Joint Direct Attack Munitions, or JDAMs, made by Boeing (NYSE:BA) Co, was considered routine at the time, before the start last week of the fiercest hostilities in the region in years.

There were no objections at the time by the Democratic and Republican leaders of the congressional foreign affairs committees that review such sales, aides said.

Asked for comment, a State Department spokesperson noted that the department is restricted under federal law and regulations from publicly commenting on or confirming details of licensing activity related to direct commercial sales like the JDAMs agreement.

"We remain deeply concerned about the current violence and are working towards achieving a sustainable calm," the spokesperson said.

© Reuters. Israeli soldiers stand by an artillery unit as it fires near the border between Israel and the Gaza strip, on the Israeli side May 17, 2021. REUTERS/Amir Cohen

Strong support for Israel is a core value for both Democratic and Republican members of the U.S. Congress, despite calls from a few of the most progressive Democrats to take a tougher stance against the government of Israeli President Benjamin Netanyahu.

U.S. law allows Congress to object to weapons sales, but it is unlikely to do so in this case. Because Israel is among a handful of countries whose military deals are approved under an expedited process, the typical window for objecting will close before lawmakers can pass a resolution of disapproval, even if they were inclined to.

Latest comments

Nasty world, they make money with wars!!!
expect more wars under Biden
expect capitulation to Russian interests if Trump is re-elected in 2024.
historically that is not true.
  well, the 3 recent wars were started by republican presidents (Gulf War 1, Afganistan, Iraq), the 3 wars before that (WWI, WWII, and majority of Vietnam War) were started by democrat presidents, so I would say it's basically a tie
So sad. And an “expedited process” stops disapproval. Defund the government.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.